Professor Tonia Vincent is part of an interdisciplinary team from Oxford University leading a major new initiative which aims to redefine human-based research models for greater understanding of disease and the acceleration of new medicines.
Researchers from the Kennedy Institute are part of a UK-wide consortium that has been awarded a \u00a3644K BBSRC Network Grant to establish the Microbiome Innovation Network (Microbiome-Net).
Teaming up with scientists and clinician-scientists at the University of Birmingham, and with 2025 Nobel Prize winner Professor Shimon Sakaguchi from Osaka University, Professor Calliope Dendrou from the Kennedy Institute will work on a major research programme to transform the treatment of autoimmune diseases by halting chronic inflammation at its source.
Jelena Bezbradica Mirkovic, Audrey Gerard, Karthik Ramasamy and Sarah Snelling have been awarded the title of \u2018Full Professor\u2019 in the University of Oxford\u2019s 2025 Recognition of Distinction exercise.
Julia Karjalainen, A DPhil candidate at the Kennedy Institute, has been awarded a competitive Boehringer Ingelheim Fonds PhD fellowship to study neuro-immune interactions in skin disease.
Dr Mariana Borsa, Postdoctoral Researcher in autophagy and ageing, will leave the Kennedy Institute to start an exciting new chapter in Switzerland as a Principal Investigator.
NDORMS has been awarded the designation of a EULAR Centre of Excellence for a third consecutive term. This prestigious award is a recognition of the department\u2019s contribution to advancing the science of rheumatic and musculoskeletal diseases.
Dr Fr\u00e4nze Progatzky, Principal Investigator in Tissue Biology and Wellcome Career Development Fellow, has been awarded a Lister Institute Research Prize to support her outstanding science.
Mikalena Xenophontos, a DPhil candidate at NDORMS, has been awarded an MRC Clinical Research Training Fellowship to explore the role of glial cells in rheumatoid arthritis.
A new Medical Research Council Centre of Research Excellence (MRC CoRE) will investigate how the environment interacts with our immune system to trigger chronic inflammatory diseases, such as asthma, chronic obstructive pulmonary disorder (COPD) and inflammatory bowel disease (IBD).
Researchers have been able to see what happens in the inflamed joints of children with arthritis, giving insight into why treatments affect children differently.
Kennedy researchers have uncovered new clues about how immune memory exacerbates inflammation in rheumatoid arthritis, which could lead to better ways to control the disease.
Kennedy DPhil student Chrissy Bolton has been awarded Best Abstract in Basic and Translational Science at the European Alliance of Associations for Rheumatology 2025 (EULAR) conference.
Professor Marco Fritzsche from the Kennedy Institute of Rheumatology, is co-leading a research project that has been awarded a \u00a31.4 million Programme Foundation Award from Cancer Research UK, to investigate how physical forces within tumours affect the ability of a type of white blood cell to attack and eliminate cancer cells.
Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs) - a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and revolutionise cancer treatment for patients.
A study has found that a subtype of macrophage is found in the perivascular niche early in the development of inflammatory arthritis, attracting more immune cells and potentially driving inflammation. Targeting these cells with new therapies could be a potential avenue for treating inflammatory arthritis before it develops in severity.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues\u2014addressing a major challenge in current immunotherapy.
Biophotonic Correlative Optical Platform (BioCOP), which is located at the Rosalind Franklin Institute (the Franklin), has entered its next phase of development of calibration and benchmarking. The instrument is now assembled, and the team will start testing it with model systems and real biological problems.
A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
![\"Linh](\"https://www.kennedy.ox.ac.uk/news/linh-nguyen-receives-lee-placito-research-fellowship/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n